EMA — authorised 19 April 2024
- Application: EMEA/H/C/006194
- Marketing authorisation holder: Incyte Biosciences Distribution B.V.
- Local brand name: Zynyz
- Indication: Squamous cell carcinoma of the anal canal (SCAC) Zynyz is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). Merkel cell carcinoma (MCC) Zynyz is indicated as monotherapy for the first line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation therapy.
- Pathway: orphan
- Status: approved
The European Medicines Agency (EMA) approved ZYNYZ for use in the European Union on 19 April 2024. ZYNYZ is indicated for the treatment of two types of cancer: squamous cell carcinoma of the anal canal (SCAC) and Merkel cell carcinoma (MCC). For SCAC, ZYNYZ is used in combination with carboplatin and paclitaxel for first-line treatment of adult patients with metastatic or inoperable locally recurrent SCAC. For MCC, ZYNYZ is used as monotherapy for first-line treatment of adult patients with metastatic or locally advanced MCC not amenable to curative surgery or radiation therapy.